March of Dimes Responds To Ther-Rx
White Plains, New York | Friday, April 01, 2011
Ther-Rx Corporation’s decision to reduce the list price of Makena to $690 and to expand patient financial assistance are steps in the right direction toward making an FDA-approved progesterone therapy product more widely available. Nevertheless, the March of Dimes has decided to exercise our right to terminate our current contract and sever all professional relationships with Ther-Rx. The company's handling of the launch of Makena, and the initial list price, were highly unsatisfactory and unacceptable to the March of Dimes and the families we represent. The March of Dimes will continue to explore all options for ensuring access to progesterone therapy for all medically eligible women. Access for women to treatment to prevent premature birth is and always has been our paramount concern. We hope that the controversy surrounding Makena has helped raise awareness that progesterone therapy is a safe and effective treatment for prevention of preterm birth and that more obstetricians will consider it for appropriate patients.
About March of Dimes
The March of Dimes is the leading nonprofit organization for pregnancy and baby health. For more than 75 years, moms and babies have benefited from March of Dimes research, education, vaccines, and breakthroughs.
For the latest resources and health information, visit our websites marchofdimes.org and nacersano.org. To participate in our annual signature fundraising event, visit marchforbabies.org. If you have been affected by prematurity or birth defects, visit our shareyourstory.org community to find comfort and support. For detailed national, state and local perinatal statistics, visit peristats.org. You can also find us on Facebook or follow us on Twitter.